GliMR: Cross-Border Collaborations to Promote Advanced MRI Biomarkers for Glioma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F21%3A00073357" target="_blank" >RIV/00159816:_____/21:00073357 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/21:00120908

Výsledek na webu

<a href="https://link.springer.com/article/10.1007/s40846-020-00582-z" target="_blank" >https://link.springer.com/article/10.1007/s40846-020-00582-z</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s40846-020-00582-z" target="_blank" >10.1007/s40846-020-00582-z</a>

Jazyk výsledku

angličtina

Název v původním jazyce

GliMR: Cross-Border Collaborations to Promote Advanced MRI Biomarkers for Glioma

Popis výsledku v původním jazyce

Purpose There is an annual incidence of 50,000 glioma cases in Europe. The optimal treatment strategy is highly personalised, depending on tumour type, grade, spatial localization, and the degree of tissue infiltration. In research settings, advanced magnetic resonance imaging (MRI) has shown great promise as a tool to inform personalised treatment decisions. However, the use of advanced MRI in clinical practice remains scarce due to the downstream effects of siloed glioma imaging research with limited representation of MRI specialists in established consortia; and the associated lack of available tools and expertise in clinical settings. These shortcomings delay the translation of scientific breakthroughs into novel treatment strategy. As a response we have developed the network &quot;Glioma MR Imaging 2.0&quot; (GliMR) which we present in this article. Methods GliMR aims to build a pan-European and multidisciplinary network of experts and accelerate the use of advanced MRI in glioma beyond the current &quot;state-of-the-art&quot; in glioma imaging. The Action Glioma MR Imaging 2.0 (GliMR) was granted funding by the European Cooperation in Science and Technology (COST) in June 2019. Results GliMR&apos;s first grant period ran from September 2019 to April 2020, during which several meetings were held and projects were initiated, such as reviewing the current knowledge on advanced MRI; developing a General Data Protection Regulation (GDPR) compliant consent form; and setting up the website. Conclusion The Action overcomes the pre-existing limitations of glioma research and is funded until September 2023. New members will be accepted during its entire duration.

Název v anglickém jazyce

GliMR: Cross-Border Collaborations to Promote Advanced MRI Biomarkers for Glioma

Popis výsledku anglicky

Purpose There is an annual incidence of 50,000 glioma cases in Europe. The optimal treatment strategy is highly personalised, depending on tumour type, grade, spatial localization, and the degree of tissue infiltration. In research settings, advanced magnetic resonance imaging (MRI) has shown great promise as a tool to inform personalised treatment decisions. However, the use of advanced MRI in clinical practice remains scarce due to the downstream effects of siloed glioma imaging research with limited representation of MRI specialists in established consortia; and the associated lack of available tools and expertise in clinical settings. These shortcomings delay the translation of scientific breakthroughs into novel treatment strategy. As a response we have developed the network &quot;Glioma MR Imaging 2.0&quot; (GliMR) which we present in this article. Methods GliMR aims to build a pan-European and multidisciplinary network of experts and accelerate the use of advanced MRI in glioma beyond the current &quot;state-of-the-art&quot; in glioma imaging. The Action Glioma MR Imaging 2.0 (GliMR) was granted funding by the European Cooperation in Science and Technology (COST) in June 2019. Results GliMR&apos;s first grant period ran from September 2019 to April 2020, during which several meetings were held and projects were initiated, such as reviewing the current knowledge on advanced MRI; developing a General Data Protection Regulation (GDPR) compliant consent form; and setting up the website. Conclusion The Action overcomes the pre-existing limitations of glioma research and is funded until September 2023. New members will be accepted during its entire duration.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

20601 - Medical engineering

Projekt

<a href="/cs/project/LTC20027" target="_blank" >LTC20027: Mapping of glioma heterogeneity and infiltration extend by MR imaging biomarkers</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Medical and Biological Engineering

ISSN

1609-0985

e-ISSN

—

Svazek periodika

41

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

115-125

Kód UT WoS článku

000599062700001

EID výsledku v databázi Scopus

—